Enhancement of Preventive Vaccination Approaches for Children with Health Problems: Prospective Cohort Study Results
https://doi.org/10.15690/pf.v18i6.2328
Abstract
Background. Modern preventive vaccination is intended to protect and enhance the health of every person considering age and health issues. Vaccination of children with chronic diseases in our country remains extremely topical and arguable problem that associated with many pending issues for doctors of various specialties, including those working as primary care specialists.
Objective. The aim of the study is to develop major approaches and to prove scientifically the efficacy and safety of preventive vaccination for children with various chronic diseases.
Methods. We have conducted comprehensive study of 100 children aged from 1 month to 17 years 11 months. Children were divided into 4 groups according to the specific disease. Vaccinal and infectious history was analyzed. The post-vaccination period was estimated due to the results of the questionnaire completed by parents. Vaccination immunogenicity was estimated based on the results of the level of specific antibodies to various controlled infections (measles, rubella, parotitis, hepatitis B, pertussis, haemophilus influenza type b).
Results. Protective titers of antibodies against haemophilus influenza type b were revealed in 96.2% of all examined patients, tetanus and hepatitis B — in 95.2%, against pertussis — in 92.5%, rubella — in 91%, measles — in 87.5%, parotitis — in 71.9%, chickenpox — in 69% children a month after the completed vaccination. The postvaccinal period was characterized as favorable in most patients. Major changes in overall health status occurred after vaccination in 42% of children was the following: subfebrile fever, capriciousness, or fatigue. Local reactions have developed only in 15% of cases.
Conclusion. The results of this study have demonstrated the preventive vaccination efficacy and safety in children with various chronic diseases
About the Authors
Marina V. FedoseenkoRussian Federation
Marina V. Fedoseenko, PhD
eLibrary SPIN: 6339-5386
10 Fotievoy Str., 119333 Moscow
Disclosure of interest:
receiving grants for lecturing from Pfizer, Sanofi Pasteur, MSD companies
Leyla S. Namazova-Baranova
Russian Federation
Leyla S. Namazova-Baranova, MD, PhD, Professor, Academician of the RAS
eLibrary SPIN: 1312-2147
10 Fotievoy Str., 119333 Moscow
Disclosure of interest:
receiving research grants from pharmaceutical companies Pierre Fabre LLC, GenzymeEurope B.V., AstraZeneca PharmaceuticalsPLC, Gilead/PRA “Pharmaceutical Research Associates CIS”, “Bionorica“, TevaBrandedPharmaceuticalProducts R&D, Inc / “PPDDevelopment LLC (Smolensk)” LLC, “Stallerzhen S.A.” / “Quintiles GMBH” (Austria)
Elena A. Vishneva
Russian Federation
Elena A. Vishneva, MD, PhD
10 Fotievoy Str., 119333 Moscow
Disclosure of interest:
the absence of a reportable conflict of interests
Svetlana V. Tolstova
Russian Federation
Svetlana V. Tolstova
10 Fotievoy Str., 119333 Moscow
Disclosure of interest:
the absence of a reportable conflict of interests
Arevaluis M. Selvyan
Russian Federation
Arevaluis M. Selvyan
10 Fotievoy Str., 119333 Moscow
Disclosure of interest:
the absence of a reportable conflict of interests
Tatiana A. Kaliuzhnaia
Russian Federation
Tatiana A. Kaliuzhnaia, PhD
e-Library SPIN: 5155-8995
10 Fotievoy Str., 119333 Moscow
Disclosure of interest:
the absence of a reportable conflict of interests
Firuza Ch. Shakhtakhtinskaya
Russian Federation
Firuza Ch. Shakhtakhtinskaya, PhD
10 Fotievoy Str., 119333 Moscow
Disclosure of interest:
the absence of a reportable conflict of interests
Margarita A. Soloshenko
Russian Federation
Margarita A. Soloshenko, PhD
10 Fotievoy Str., 119333 Moscow
Disclosure of interest:
the absence of a reportable conflict of interests
Tatiana E. Privalova
Russian Federation
Tatiana E. Privalova, PhD
10 Fotievoy Str., 119333 Moscow
Disclosure of interest:
the absence of a reportable conflict of interests
Maria V. Fominyh
Russian Federation
Maria V. Fominykh
10 Fotievoy Str., 119333 Moscow
Disclosure of interest:
the absence of a reportable conflict of interests
Tatiana E. Zinovyeva
Russian Federation
Tatiana E. Zinovyeva
12 Entuziastov Sh., 111024 Moscow
Disclosure of interest:
the absence of a reportable conflict of interests
References
1. Toor J, Echeverria-Londono S, Li X, et al. Lives saved with vaccination for 10 pathogens across 112 countries in a pre-COVID-19 world. eLife. 2021;10:e67635. doi: 10.7554/eLife.67635
2. Vaktsiny i vaktsinatsiya: National leadership. Zverev VV, Khaitova RM, eds. Moscow: GEOTAR-Media; 2014. 640 p. (In Russ).
3. Keja K, Chan C, Hayden G, Henderson RH. Expanded programme on immunization. World Health Stat Q. 1988:41(2):59–63.
4. Bulletin of the World Health Organization. (In Russ). Available online: http://www.who.int/bulletin/volumes/92/5/14-020514/ru. Accessed on November 18, 2021.
5. Pelton SI, Shea KM, Farkouh RA, et al. Rates of pneumonia among children and adults with chronic medical conditions in Germany. BMC Infect Dis. 2015;15:470–477. doi: 10.1186/s12879-015-1162-y
6. Fedoseenko MV, Galitskaya MG, Namazova-Baranova LS. Vaccination of children with severe chronic diseases. Algorithm for the immunologist physician. Pediatricheskaya farmakologiya — Pediatric pharmacology. 2010;7(6):16–21. (In Russ.) (In Russ).
7. Vaktsinatsiya detei s narushennym sostoyaniem zdorov’ya. Kostinov MP, ed. Moscow: 4Mpress; 2013. 432 p. (In Russ).
8. Whittaker E, Goldblatt D, McIntyre P and Levy O. Neonatal Immunization: Rationale, Current State, and Future Prospects. Front. Immunol. 2018. 9:532. doi: 10.3389/fimmu.2018.00532
9. Rubin LG, Levin MJ, Ljungman P, et al. 2013 IDSA Clinical Practice Guideline for Vaccination of the Immunocompromised Host. Clin Infect Dis. 2014;58(3):309–318. doi: 10.1093/cid/cit816
10. Okwo-Bele JM, Cherian T. The expanded programme on immunization: a lasting legacy of smallpox eradication. Vaccine. 2011;29(4):D74–D79. doi: 10.1016/j.vaccine.2012.01.080
11. Vaktsinoprofilaktika pnevmokokkovoi infektsii u detei: Guidelines. Moscow: Union of Pediatricians of Russia; 2018. 27 p. (In Russ).
12. Vaktsinoprofilaktika menongokokkovoi infektsii u detei: Guidelines. Moscow: Union of Pediatricians of Russia; 2020. 32 p. (In Russ).
13. Федосеенко М.В., Галицкая М.Г., Намазова-Баранова Л.С. Вакцинация детей с тяжелым течением хронических болезней. Алгоритмы врача-иммунолога // Педиатрическая фармакология. 2010; 7(6): 16-21
14. Immunization Agenda 2030: A Global Strategy To Leave No One Behind. Project for WHO. (In Russ). https://www.who.int/ru/publications/m/item/immunisation-agenda-2030-a-global-strategy-to-leave-noone-behind.
15. Philip RK, Attwell K, BreuerT, et al. Life-course immunization as a gateway to health. Exp Rev Vaccines. 2018;17(10):851–864. doi: 10.1080/14760584.2018.1527690
16. Medical guidance 3.3.1.1095-02 “Meditsinskie protivopokazaniya k provedeniyu profilakticheskikh privivok preparatami natsional’nogo kalendarya privivok” (approved by the Chief State Sanitary Doctor of the Russian Federation on January 9, 2002). (In Russ).
17. Recommended Immunization Schedule for Children and Adolescents Aged 18 Years or Younger, United States, 2018. Available online: https://publications.aap.org/pediatrics/article/141/3/e20180083/37621/Recommended-Childhoodand-Adolescent-Immunization?autologincheck=redirected. Accessed on November 18, 2021.
18. Steinglass R. Routine immunization: an essential but wobbly platform. Glob Health Sci Pract. 2013;1(3):295–301. doi: 10.9745/GHSP-D-13-00122
19. Vaccine schedules in all countries of the European Union. Available online: https://vaccine-schedule.ecdc.europa.eu. Accessed on November 18, 2021.
20. Namazova-Baranova LS, Fedoseenko MV, Baranov AA. New Horizons of National Immunization Calendar. Voprosy sovremennoi pediatrii — Current Pediatrics. 2019;18(1):13–30. (In Russ). . doi: 10.15690/vsp.v18i1.1988
21. Measles cases spike globally due to gaps in vaccination coverage. WHO; November 2018. (In Russ). https://www.who.int/ru/news-room/detail/29-11-2018-measles-casesspike-globally-due-to-gaps-in-vaccination-coverage.
22. Information on infectious and parasitic diseases in the Russian Federation for January-December 2018. Federal Service for Supervision of Consumer Rights Protection and Human Welfare; 2019.. (In Russ). https://www.rospotrebnadzor.ru/activities/statistical-materials/statictic_details.php?ELEMENT_ID=11277.
23. Намазова-Баранова Л.С., Федосеенко М.В., Гринчик П.Р., Гирина А.А., Ковалёв С.В., Мазоха А.В., Макушина Е.Д., Малинина Е.И., Мусихина А.Ю., Перминова О.А., Пленсковская Н.Ю., Привалова Т.Е., Рычкова О.А., Семериков В.В., Фоминых М.В., Фуголь Д.С., Якимова Н.В., Ртищев А.Ю., Русинова Д.С. Привитость и охват иммунизацией в соответствии с национальным календарем профилактических прививок детского населения: одномоментное многоцентровое исследование. Педиатрическая фармакология. 2021;18(2):110–117. doi: 10.15690/pf.v18i2.2218
24. Medical guidance 3.3.1.1123-02 “Monitoring postvaktsinal’nykh oslozhnenii i ikh profilaktika” (approved by the Chief State Sanitary Doctor of the Russian Federation on May 26, 2002). (In Russ).
25. Medical guidance 3.3.1.1123-02 “Poryadok provedeniya profilakticheskikh privivok” (approved by the Chief State Sanitary Doctor of the Russian Federation on Marth 4, 2004). (In Russ).
26. 24McLean HQ, Fiebekorn AP, Temte JL, et al. Prevention of measles, rubella, congenital rubella syndrome, and mumps, 2013: summary recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2013;62(RR04):1–34.
27. Varicella vaccine. WHO position paper. (In Russ). https://www.who.int/immunization/varicella_RUS.pdf?ua=1 .
28. Al-Mekaini LA, Kamal SM, Al-Jabri O, et al. Seroprevalence of vaccine-preventable diseases among young children in the United Arab Emirates. Int J Infect Dis. 2016;50:67–71. doi: 10.1016/j.ijid.2016.07.012
Review
For citations:
Fedoseenko M.V., Namazova-Baranova L.S., Vishneva E.A., Tolstova S.V., Selvyan A.M., Kaliuzhnaia T.A., Shakhtakhtinskaya F.Ch., Soloshenko M.A., Privalova T.E., Fominyh M.V., Zinovyeva T.E. Enhancement of Preventive Vaccination Approaches for Children with Health Problems: Prospective Cohort Study Results. Pediatric pharmacology. 2021;18(6):469-482. (In Russ.) https://doi.org/10.15690/pf.v18i6.2328